TABLE 3.
Impact of DISC vaccine on GPCMV transmission, based on frequencies of GPCMV-positive pups in each specific tissue group
| Vaccine group (n) | No. (%) of pups positive for GPCMV in specific tissue [P value]a |
No. (%) of CMV+ pupsb [P value] | |||
|---|---|---|---|---|---|
| Lung | Liver | Spleen | Brain | ||
| DISM (51) | 7 (13.7) [0.0001] | 2 (3.9) [0.0013] | 2 (3.9) [0.0001] | 5 (9.8) [0.0006] | 12 (23.5)[0.0001] |
| NOD controls (29) | 17 (58.62) | 9 (31.03) | 19 (65.52) | 13 (44.83) | 22 (75.9) |
a
P values are based on comparisons using Fisher's exact test of the number of animals CMV+ for the specific organ in the vaccinated group versus the NOD control group.
b
Number (percentage) of pups in which GPCMV was detected in at least one organ.